Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,442JPY
12 Dec 2017
Change (% chg)

¥6 (+0.42%)
Prev Close
¥1,436
Open
¥1,438
Day's High
¥1,448
Day's Low
¥1,438
Volume
6,368,500
Avg. Vol
7,389,190
52-wk High
¥1,688
52-wk Low
¥1,332

Chart for

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.70
Market Cap(Mil.): ¥2,970,830.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.44

Financials

  Industry Sector
P/E (TTM): -- 31.83 15.71
EPS (TTM): -- -- --
ROI: -- 15.03 31.93
ROE: -- 16.54 16.16

BRIEF-Astellas acquires Mitobridge under existing collaboration

* SAYS ‍MITOBRIDGE WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF ASTELLAS FOLLOWING CLOSE OF ACQUISITION​ Source text for Eikon: Further company coverage:

Nov 30 2017

Astellas faces U.S. probe over patient assistance charity support

BOSTON Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

Nov 15 2017

Astellas faces U.S. probe over patient assistance charity support

BOSTON, Nov 15 Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

Nov 15 2017

BRIEF-Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin

* Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer

Nov 08 2017

BRIEF-Astellas Pharma completes share repurchase

* Says it completed repurchase of 49.3 million shares of its common stock, for 70 billion yen in total, as of Oct. 31

Oct 31 2017

BRIEF-Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D

* Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​

Oct 31 2017

Swiss stocks - Factors to watch on Oct 23

ZURICH, Oct 23 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 9,254 points on Monday, according to premarket indications by bank Julius Baer .

Oct 23 2017

Fitch Revises Beijing Capital Development's Outlook to Negative, Affirms Rating at 'BBB-'

(The following statement was released by the rating agency) HONG KONG, October 18 (Fitch) Fitch Ratings has revised Beijing Capital Development Holding (Group) Co., Ltd.'s (known by its abbreviated Chinese name Shokai Group) Outlook to Negative from Stable. Shokai Group's Long-Term Foreign-Currency Issuer Default Rating (IDR) has been affirmed at 'BBB-', and its senior unsecured rating and the ratings of all outstanding bonds have also been affirmed at 'BBB-'. A full list of rating actions is at

Oct 18 2017

BRIEF-FDA grants fast track status to Astellas for acute myeloid leukemia drug

* U.S. FDA grants fast track designation to Astellas for development of gilteritinib in relapsed or refractory acute myeloid leukemia Source text for Eikon: Further company coverage:

Oct 10 2017

BRIEF-Astellas and Seattle Genetics initiate trial of enfortumab vedotin for ureter cancer patients

* Astellas and Seattle Genetics initiate pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer

Oct 10 2017

Earnings vs. Estimates